Low-dose interferon-alpha 2b combined with hydroxyurea versus hydroxyurea alone for chronic myelogenous leukemia

被引：0
|
作者：
Louwagie, A [1 ]
Delannoy, A [1 ]
KluinNelemans, JC [1 ]
机构：
[1] LEIDEN UNIV HOSP,DEPT HEMATOL,2333 AA LEIDEN,NETHERLANDS
来源：
BONE MARROW TRANSPLANTATION | 1996年 / 17卷
关键词：
CML; IFN-alpha; cytogenetics; randomized trial; therapy;
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：S19 / S20
页数：2
相关论文
共 50 条
  • [1] Randomized study on hydroxyurea alone versus hydroxyurea combined with low-dose interferon-α2b for chronic myeloid leukemia
    Kluin-Nelemans, JC
    Delannoy, A
    Louwagie, A
    Le Cessie, S
    Hermans, J
    van der Burgh, JF
    Hagemeijer, AM
    Van den Berghe, H
    [J]. BLOOD, 1998, 91 (08) : 2713 - 2721
  • [2] A randomized study on hydroxyurea alone versus hydroxyurea combined with low dose interferon alpha-2b for chronic myeloid leukemia.
    Delannoy, A
    Louwagie, AC
    KluinNelemans, JC
    vandenBurgh, JF
    Boogaerts, MA
    Bosly, A
    Michaux, JL
    Zachee, P
    Hagemeijer, A
    VandenBerghe, H
    [J]. BLOOD, 1997, 90 (10) : 2304 - 2304
  • [3] Questions raised by the benelux CML study group:: Results from the randomized study with hydroxyurea alone versus hydroxyurea combined with low-dose interferon-α 2b for chronic myeloid leukemia
    Kantarjian, HM
    Talpaz, M
    [J]. BLOOD, 1998, 92 (08) : 2984 - 2986
  • [4] RANDOMIZED COMPARISON OF INTERFERON-ALPHA WITH BUSULFAN AND HYDROXYUREA IN CHRONIC MYELOGENOUS LEUKEMIA
    HEHLMANN, R
    HEIMPEL, H
    HASFORD, J
    KOLB, HJ
    PRALLE, H
    HOSSFELD, DK
    QUEISSER, W
    LOFFLER, H
    HOCHHAUS, A
    HEINZE, B
    GEORGII, A
    BARTRAM, CR
    GRIESSHAMMER, M
    BERGMANN, L
    ESSERS, U
    FALGE, C
    QUEISSER, U
    MEYER, P
    SCHMITZ, N
    EIMERMACHER, H
    WALTHER, F
    FETT, W
    KLEEBERG, UR
    KABISCH, A
    NERL, C
    ZIMMERMANN, R
    MEURET, G
    TICHELLI, A
    KANZ, L
    TIGGES, FJ
    SCHMID, L
    BROCKHAUS, W
    TOBLER, A
    REITER, A
    PERKER, M
    EMMERICH, B
    VERPOORT, K
    ZANKOVICH, R
    VONWUSSOW, P
    PRUMMER, O
    THIELE, J
    BUHR, T
    CARBONELL, F
    ANSARI, H
    [J]. BLOOD, 1994, 84 (12) : 4064 - 4077
  • [5] Questions raised by the benelux CML study group:: Results from the randomized study with hydroxyurea alone versus hydroxyurea combined with low-dose interferon-α 2b for chronic myeloid leukemia -: Response
    Kluin-Nelemans, JC
    Delannoy, A
    Louwagie, A
    [J]. BLOOD, 1998, 92 (08) : 2986 - 2987
  • [6] RANDOMIZED COMPARISON OF INTERFERON-ALPHA WITH BUSULFAN AND HYDROXYUREA IN CHRONIC MYELOGENOUS LEUKEMIA (CML)
    HEHLMANN, R
    HEIMPEL, H
    HASFORD, J
    KOLB, HJ
    PRALLE, H
    HOSSFELD, DK
    QUEISSER, W
    LOFFLER, H
    HOCHHAUS, A
    HEINZE, B
    ANSARI, H
    [J]. BLOOD, 1994, 84 (10) : A382 - A382
  • [7] CYTOGENETIC REMISSIONS IN CHRONIC MYELOGENOUS LEUKEMIA USING INTERFERON ALPHA-2A AND HYDROXYUREA WITH OR WITHOUT LOW-DOSE CYTOSINE-ARABINOSIDE
    GUILHOT, F
    DREYFUS, B
    BRIZARD, A
    HURET, JL
    TANZER, J
    [J]. LEUKEMIA & LYMPHOMA, 1991, 4 (01) : 49 - 55
  • [8] Low dose cytarabine with hydroxyurea versus hydroxyurea alone in high risk chronic myeloid leukemia patients
    Tripathi, AK
    Tandon, V
    Sarkari, M
    Chaturvedi, R
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1998, 102 (01) : 185 - 185
  • [9] Randomized study of the combination of hydroxyurea and interferon alpha versus hydroxyurea monotherapy during the chronic phase or chronic myelogenous leukemia (CML Study II)
    Hehlmann, R
    Heimpel, H
    Hossfeld, DK
    Hasford, J
    Kolb, HJ
    Loffler, H
    Pralle, H
    Queisser, W
    Hochhaus, A
    Tichelli, A
    Fett, W
    Schmitz, N
    Reiter, A
    Griesshammer, M
    Pfeifer, W
    Baumler, M
    Kamp, T
    Tobler, A
    Eimermacher, H
    Kuse, R
    Berger, U
    Ansari, H
    [J]. BONE MARROW TRANSPLANTATION, 1996, 17 : S21 - S24
  • [10] LOW-DOSE INTERFERON-ALPHA IN CHRONIC MYELOID-LEUKEMIA
    TALPAZ, M
    KANTARJIAN, H
    [J]. ANNALS OF INTERNAL MEDICINE, 1995, 122 (09) : 728 - 728
12345